Sellas signs up PPD as a preferred partner

By Zachary Brennan

- Last updated on GMT

Related tags Cancer

PPD gets Sellas deal
PPD gets Sellas deal
Swiss-based Sellas Life Sciences Group has signed a definitive master service agreement with CRO Pharmaceutical Product Development (PPD) to advance and expand clinical and regulatory development.

Angelos M. Stergiou, CEO & chairman of Sellas, said: "The assets we currently hold, mainly Zolpidem for central nervous indications and the WT1 cancer vaccine, initially will be used across five late-stage indications: Zolpidem for Parkinson's Disease and Progressive Supranuclear Palsy, and WT1 for Acute Myeloid Leukemia, Mesothelioma, Multiple Myeloma and subsequently ovarian cancer, lung cancer, prostate cancer and colon cancer​.

PPD's “willingness to offer commercial terms tailored to our specific needs​” was also cited as a reason for their selection.


Sellas has an exclusive global collaboration and license agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development, marketing and commercialization of MSK's proprietary WT1 cancer vaccine.

Sellas also holds global rights of Zolpidem for the indications of Parkinson's Disease (PD) and Progressive Supranuclear Palsy (PSP), as well as other basal ganglia disorders.

"We are pleased that Sellas has chosen us as its CRO partner of choice​," said Paul Colvin, PPD's executive vice president of global clinical development. "PPD's deep capabilities and consultative approach are instrumental in helping the emerging biotech industry deliver on its pipeline promise. We offer clients proven expertise in neuroscience , oncology and other therapeutic areas. PPD's resources and experience in pharmaceutical development allow us to provide needed support for Sellas' clinical and regulatory activities at each stage of the development of Sellas' two promising assets​."

Dr. Miltiadis Sougioultzoglou, executive vice president of Sellas, added: "We strive for strong and effective collaborations and currently have disruptive technologies in our portfolio in blockbuster markets and continue to seek innovative product candidates and technologies that will complement and strengthen our product portfolio​."

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more